ANPEP and metabolic syndrome: These studies strongly support that concept that increasing plasma APN levels may be an effective therapeutic strategy to inhibit increased vascular inflammation and accelerated atherosclerosis, especially relevant to cardiovascular complications triggered by RAS activation in the metabolic syndrome.